Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 12/20 | 0.55 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.39 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Beauvericin SCHEMBL22510041 | 1.00 | ABCB1 (0.55) | ABCB1CAPN1HDAC6GFERCES2 | |
| Beauvericin SCHEMBL29355 | 1.00 | ABCB1 (0.55) | ABCB1CAPN1HDAC6GFERCES2 | |
| Beauvericin SCHEMBL6452789 | 1.00 | ABCB1 (0.55) | ABCB1CAPN1HDAC6GFERCES2 | |
| SCHEMBL30932793 | 1.00 | ABCB1 (0.55) | ABCB1CAPN1HDAC6GFERCES2 | |
| SCHEMBL29519838 | 1.00 | ABCB1 (0.55) | ABCB1CAPN1HDAC6GFERCES2 | |
| SCHEMBL17520706 | 0.94 | ABCB1 (0.53) | ABCB1CAPN1HDAC6GFER | |
| SCHEMBL17520687 | 0.94 | ABCB1 (0.53) | ABCB1CAPN1HDAC6GFER | |
| SCHEMBL17520688 | 0.94 | ABCB1 (0.53) | ABCB1CAPN1HDAC6GFER | |
| Beauvericin A SCHEMBL30278897 | 0.92 | ABCB1 (0.49) | ABCB1HDAC6MMP1MMP3MMP9 | |
| SCHEMBL30278900 | 0.92 | ABCB1 (0.49) | ABCB1HDAC6MMP1MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150306068-A1 | COMPOUNDS AND RELATED METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-10-29 | — | — | US | disclosed |
| US-20150306068-A1 | COMPOUNDS AND RELATED METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-10-29 | — | — | US | disclosed |
| US-9114130-B2 | Compounds and related methods for treatment of neurodegenerative diseases | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-08-25 | — | — | US | disclosed |
| US-9114130-B2 | Compounds and related methods for treatment of neurodegenerative diseases | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-08-25 | — | — | US | disclosed |
| US-20140329791-A1 | COMPOUNDS AND RELATED METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329791-A1 | COMPOUNDS AND RELATED METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329791-A1 | COMPOUNDS AND RELATED METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | MAPT, PSEN2, PSEN1 | ABCB1 1684/4885CAPN1 449/4885HDAC6 52/4885 |
| US-20150306068-A1 | COMPOUNDS AND RELATED METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | MAPT, PSEN2, PSEN1 | ABCB1 1684/4885CAPN1 449/4885HDAC6 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.